Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021, is set to raise $300 million in its first financing round since the deal. The round, led by Abu Dhabi Investment Authority’s (ADIA) subsidiary Platinum Orchid and Government of Singapore Investment Corp (GIC), includes participation from China Life Private Equity Investment and Xinda Kunpeng (Shenzhen) Equity Investment.
Financing Details
The capital raise aims to optimize Taibang Biologic’s capital structure and strengthen its market position in mainland China. Proceeds will fund plasma station expansion, new product development, and other strategic initiatives.
Company Background
Founded in Beijing in 2002, Taibang Biologic focuses on plasma collection and the development of plasma-based products such as immunoglobulin. Its pipeline also includes non-blood products like artificial dura mater, artificial nerve sheath, and neurosurgery tools. The firm operates across all medical markets in China.-Fineline Info & Tech
